Australian therapeutic antibody development company Patrys (ASX:PAB) has announced results from a recently completed pre-clinical study that it says validates the potential to use its full-size IgG deoxymab, PATDX3, for synthetic lethality strategies to treat relevant cancers. …
Patrys' says preclinical data supports synthetic lethality mechanism
March 15, 2023 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Medicines Australia calls for Budget action to restore access to innovative medicines
February 3, 2026 - - Latest News -
Survey exposes deep gaps in support for Australians living with rare cancers
February 3, 2026 - - Latest News -
Juvenile Arthritis Foundation Australia seeks new CEO as Angela McKay steps down
February 3, 2026 - - Latest News -
AusBiotech and Medicines Australia unite to accelerate advanced therapies
February 3, 2026 - - Latest News -
If you're going to pay for reforms, are these the changes you want to pay for?
February 3, 2026 - - Latest News -
Arthritis Australia appoints Louise Hardy as CEO at pivotal moment for national advocacy
February 2, 2026 - - Latest News -
AusBiotech urges adoption of national life sciences strategy as global competition intensifies
February 2, 2026 - - Australian Biotech